All In Biotech

NDA 204441 · Otsuka

Jynarque

Tolvaptan · Oral · Vasopressin V2 Receptor Antagonist

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Apr 23, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

104

40 Phase 3, 3 recruiting

FAERS reports

8,701

6,653 serious, 1,432 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS LIVER INJURY JYNARQUE (tolvaptan) can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported [see Warnings and Precautions (5.1) ] . Measure ALT, AST and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months and every 3 months thereafter [see Warnings and Precautions (5.1) ] . Prompt action in response to laboratory abnormalities, signs, or symptoms indicative of hepatic injury can mitigate, but not eliminate, the risk of serious hepatotoxicity. Because of the risks of serious liver injury, JYNARQUE is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS) called the Tolvaptan for ADPKD Shared System REMS [see Warnings and Precautions (5.2) ] . WARNING: RISK OF SERIOUS LIVER...

What it is approved for

From the label in effect Sep 30, 2026.

JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). JYNARQUE is a selective vasopressin V 2 -receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) ( 1 )

Mechanism: Tolvaptan is a selective vasopressin V 2 -receptor antagonist with an affinity for the V 2 -receptor that is 1.8 times that of native arginine vasopressin (AVP). Tolvaptan affinity for the V 2 -receptor is 29 times that for the V 1a -receptor. Decreased binding of vasopressin to the V 2 -receptor in the kidney lowers adenylate cyclase activity resulting in a decrease in intracellular adenosine 3′, 5′-cyclic monophosphate (cAMP) concentrations. Decreased cAMP concentrations prevent aquaporin 2 containing vesicles from fusing with the plasma membrane, which in turn causes an increase in urine...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 23, 2018 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated · priority review NovelOrphanLetterReviewLabel
5 products under this application
  • JYNARQUE · TOLVAPTAN 45MG · TABLET, ORAL · Prescription · TE AB2
  • JYNARQUE · TOLVAPTAN 15MG · TABLET, ORAL · Prescription · TE AB2
  • JYNARQUE · TOLVAPTAN 60MG · TABLET, ORAL · Prescription · TE AB2
  • JYNARQUE · TOLVAPTAN 30MG · TABLET, ORAL · Prescription · TE AB2
  • JYNARQUE · TOLVAPTAN 90MG · TABLET, ORAL · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Tolvaptan" as an intervention, any sponsor and status, largest first.

All 104 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • thirst907
  • product dose omission issue749
  • death586
  • pollakiuria586
  • renal impairment529
  • polyuria419
  • no adverse event408
  • wrong technique in product usage process407
  • fatigue393
  • inappropriate schedule of product administration369
  • underdose361
  • blood creatinine increased345

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20091
20102
20115
201228
201333
201442
2015254
2016219
2017238
2018370
2019478
2020308
2021407
2022602
2023796
20241,345
20251,929
20261,643

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Jynarque (Tolvaptan)

2024 spending

$103M

Beneficiaries

585

5,415 claims

Per beneficiary

$176,885

$346.67 per unit

View as table
YearSpending
2020$37,490,637
2021$46,234,050
2022$60,705,731
2023$76,164,444
2024$103,477,556

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 228 on PubMed

Sponsor: Otsuka

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.